Levamisole-Adulterated Cocaine: What Toxicology Findings Can Show

Chemical detection is not the same as clinical causation

Levamisole can be identified in seized powder or biological specimens by an appropriate analytical method. Fucci reported levamisole and hydroxyzine in specific cocaine seizures analyzed by gas chromatography-mass spectrometry. Duflou and colleagues described a cocaine fatality in which levamisole was found in powder, a nasal swab, and blood.

Those reports establish detection in the materials that were tested. They do not create a rule that levamisole caused every symptom or death whenever it is present. In the Duflou case, the reported cause of death was cocaine toxicity, and the authors reported no evidence of agranulocytosis.

The reported clinical syndrome has recurring features

Gross and colleagues described four new cases and reviewed 12 earlier reports. Across those 16 patients, retiform purpura often involved the ears or extremities. Leukopenia or neutropenia was reported in more than half, ANCA findings were common, and skin pathology often showed small-vessel vasculitis, thrombotic vasculopathy, or both.

Nolan and Jen later reviewed pathologic manifestations involving skin and kidney. Their review explains why the antibody pattern may differ from classic primary vasculitis and why biopsy findings can contribute to a differential diagnosis.

These publications help identify a pattern that may warrant investigation. They do not make the pattern unique to levamisole. Vasculitis, neutropenia, renal injury, skin lesions, and abnormal antibody findings can have other causes. A case-specific evaluation must integrate history, examination, laboratory data, pathology, toxicology, and alternative explanations.

Exposure does not guarantee neutropenia

Chai and colleagues reviewed 95 cocaine-positive hospital patients who had simultaneous blood counts. Forty-seven were levamisole-positive and 48 were levamisole-negative. The groups did not show statistically significant differences in total white blood cell count, absolute neutrophil count, or absolute lymphocyte count. One patient in the levamisole-positive group and three in the negative group were neutropenic.

That finding is an important limit. Levamisole exposure does not mean that agranulocytosis or neutropenia must be present. Conversely, neutropenia in a cocaine user is not proof that levamisole caused it.

Historical prevalence figures need dates and jurisdictions

Early reports described levamisole in a large proportion of seized cocaine. Chang and colleagues cited a July 2009 United States seizure figure of 69 percent. That number is historical, tied to a particular source, place, and period. It should not be presented as the current prevalence in a different jurisdiction or year without newer representative data.

The relevant case question is narrower: Was the actual drug material or biological specimen tested for levamisole, using a method capable of identifying it?

A practical review framework

1. Identify the specimen or material in which levamisole was reported.
2. Obtain the analytical method, calibration, controls, identification criteria, reporting limit, and raw data.
3. Confirm collection time, storage, chain of custody, and specimen identity.
4. Review complete blood counts over time, including absolute neutrophil count.
5. Review the distribution and timing of skin findings, photographs, dermatology notes, and biopsy material.
6. Obtain renal, pulmonary, infectious-disease, rheumatologic, and autoimmune workups when relevant.
7. Separate cocaine toxicity from an asserted levamisole-associated effect.
8. Evaluate medications, infections, primary autoimmune disease, other adulterants, and other causes.
9. Avoid applying an old seizure prevalence estimate to an untested individual sample.

The scientifically supportable conclusion may be limited

A complete record may support confirmed levamisole exposure with compatible clinical findings. It may support exposure without a levamisole-associated syndrome. It may show a compatible syndrome without chemical confirmation. It may remain unable to distinguish among competing causes.

The correct conclusion depends on the actual specimens, methods, timeline, pathology, and differential diagnosis. The presence of one finding should not be asked to prove the entire causal chain.

Selected references

• Chai PR, Bastan W, Machan J, Hack JB, Babu KM. Levamisole exposure and hematologic indices in cocaine users. Academic Emergency Medicine. 2011;18(11):1141-1147. https://doi.org/10.1111/j.1553-2712.2011.01202.x
• Gross RL, Brucker J, Bahce-Altuntas A, et al. A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine. Clinical Rheumatology. 2011;30:1385-1392. https://doi.org/10.1007/s10067-011-1805-3
• Chang A, Osterloh J, Thomas J. Levamisole: a dangerous new cocaine adulterant. Clinical Pharmacology & Therapeutics. 2010;88(3):408-411. https://doi.org/10.1038/clpt.2010.156
• Nolan AL, Jen KY. Pathologic manifestations of levamisole-adulterated cocaine exposure. Diagnostic Pathology. 2015;10:48. https://doi.org/10.1186/s13000-015-0279-z
• Fucci N. Unusual adulterants in cocaine seized on the Italian clandestine market. Forensic Science International. 2007;172(1):e1. https://doi.org/10.1016/j.forsciint.2007.05.021
• Duflou JA, Brouwer IG, Darke S. Levamisole as an adulterant in a cocaine overdose fatality. Medical Journal of Australia. 2010;192(12):724.

General educational and marketing material only. It is not legal advice, medical advice, expert opinion, or a statement of scientific fact.